Paris (FRANCE), 09.12.2021: Data Linkage by Carenity, part of EvidentIQ demonstrates the group’s unique position to support sponsors better understanding characteristics and needs of the population, with the goal of promoting the development of better tailored health products and services.

Data Linkage is a method that helps match and merge records from different sources to get a richer dataset. This process always uses the highest standards of privacy and safety. The linkage of information enables the construction of chronological sequences of events and when used at the macro level provide valuable information for policy and research into the health and wellbeing of the population.

EvidentIQ uses significant clinical data expertise, data science analysis, and access to Carenity, their patient platform, to successfully conduct state of the art data linkage studies.

Carenity is a social network specially designed for patients with chronic diseases and their caregivers. It has more than 500,000 members in 6 countries (France, Spain, Italy, Germany, United Kingdom and the United States), which gives EvidentIQ a firsthand access to healthcare ad-hoc data if needed.

By working on projects with top 5 pharma, EvidentIQ is showing its proficiency in data generation and is offering its clients a next-level data linkage experience combining data with patients’ insights in a real-world setting using a proactive approach.

Contact us for more information on Data Linkage by EvidentIQ.

PatientLive® is a unique solution that allows to quickly survey an online community of 500,000 patients and caregiversstudies

Paris (FRANCE), 25.10.2021. Today EvidentIQ announced that its PatientLive® software is opening its doors to the clinical market. The PatientLive® platform grants access to real-time insights and reliable answers from patients and caregivers through quick polls.

PatientLive® was created by Carenity, part of the EvidentIQ group, in 2016 with the purpose of offering pharma companies a unique and fast way to get access to real-time patient insights. The Carenity team believes that guesswork is no longer enough but knows that time is also valuable. Therefore PatientLive® allows to collect real-time patient insights at a fast pace, in order to help make better strategic decisions regarding clinical patient-centric projects.
Carenity’s mission is to bring patient perspective into clinical projects to accelerate clinical trials, save costs and ensure the success of new products. With this revolutionary software, the life science industry can leverage real-time patient insights at each phase of the clinical development like early R&D, Clinical development, Clinical operations, Patient engagement, and Medical affairs.

PatientLive® can help understand patient experience (burden, Quality of life) to define Target Product Profiles, evaluate patient’s acceptance of protocol evaluation parameters and flow chart, incorporate study endpoints that are valuable from a patient perspective, optimize the design of clinical trials to facilitate patient recruitment and retention, identify preliminary feasibility for clinical projects, ensure study materials are patient-centric and easy to understand (ICF testing), and test concepts of services and tools to increase patient retention on clinical trials.

Michael Chekroun, Chief Strategy and Transformation Officer at the EvidentIQ group and Founder of Carenity, tells us about this offering:

“PatientLive® has always offered quick responses and has been characterized for its simplicity and autonomy of use. We want now to make this available for the clinical markets and keep this virtuous circle of Data for Good going.”

More about PatientLive®

PatientLive® is a unique solution that allows to quickly survey an online community of 500,000 patients and caregivers in the US and Europe with up to 36 conditions available, letting users acquire real-time insights via a five-question poll. Five types of questions including images and videos are available: single choice, multiple choice, 0 to 5 scale, text field, and numeric field. Polls on PatientLive® initiate patients data generation on topics including: disease/treatment burden, unmet needs, quality of life, services and communication message testing, and information and service needs. These early insights are invaluable for PatientLive® users as they enable better patient-centric solutions and materials and may guide the development of further non-observational studies and Real World Evidence projects.

Contact us for more information on PatientLive® by EvidentIQ.

Are you interested in Preference studies? You have heard about DCE, but not sure whether this approach is the most appropriate for you? You want to know how to define such a project and understand outcomes you would expect from?

On June 25th, 2021 our DCE webinar took place.

A Preference study is a must have for any patient-centric organization when decisions have to be made to drive a product development and ensure it meets patients’ expectations.

Among the different approaches possible, the Discrete Choice Experiment is now recognized as a gold standard and yet, few projects using this methodology have been shared.

This webinar, organized by Xtalks, showed:

• The definition of DCE
• What is the value of DCE
• Best practices implementation How to build a preference study using DCE

Access the replay

About the speakers

This live session was hosted by Lise Radoszycki Chief Operating Officer at Carenity and Nawal Bent-Ennakhil Lead Epidemiologist at Takeda.

Lise is Carenity’s Chief Operating Officer – Now part of the EvidentIQ Group. She oversees and coordinates the actions of the Data Science team which produces real-life studies, along with all digital projects and strategy to grow and engage the platform’s communities. She co-chairs Carenity’s Science and Ethics Committee.

Lise Radoszycki is a Method and Models statistic engineer with a degree from INSA (National Institute of Applied Sciences) in Toulouse, France. She also studied at the Universidad de Guadalajara (Mexico). She’s an active member of AFCRO (French CRO Association) and participates in the European think-tank Health Data Institute.

Nawal is Lead Epidemiologist at Takeda. Nawal is an epidemiologist by training. She has been leading Real World Evidence projects for more than 10 years now. She held several positions within HEOR and RWE teams and she is now lead Epidemiologist at Takeda EUCAN. Nawal has been closely managing the DCE-Preference Study Project with Carenity.

She will share her experience of collaborating with Carenity on such a project. She will explain why the DCE methodology has been chosen, what were the challenges of such methodology, how Carenity’s Team support Takeda EUCAN with the methodology its deployment and analysis of the results, what have been the main learnings of this methodology and how results will be used by Takeda EUCAN.

June 18^th, 2021, Paris (FRANCE). Today Carenity, part of the technology-driven data science group EvidentIQ, announced that its PatientLive solution is broadening its offer by entering the oncology therapeutic area. The PatientLive Oncology platform grants access to real-time insights and reliable answers from cancer patients and caregivers with quick surveys.

PatientLive was created by Carenity in 2016 with the purpose of offering pharma companies a unique, compliant, and fast way to get access to real-time patient insights. The Carenity team believes that guesswork is no longer enough, but knows that time is also valuable. This is why Patient Live allows users to get quick answers from patients to make better decisions.

Carenity’s mission is to help improve medical knowledge and care for chronic patients, including patients with cancer, which is the driving force behind the opening of 18 new PatientLive conditions. These conditions, both in hematology and solid tumors, are: bladder cancer, breast cancer, colorectal cancer, esophageal cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, liver cancer, lung cancer, mouth cancer, multiple myeloma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, skin cancer, throat cancer, thyroid cancer, and tongue cancer.

Until today, PatientLive offered access to a worldwide online panel of 500,000 patients and caregivers in the following conditions: ankylosing spondylitis, arterial hypertension, asthma, bipolar disorder, COPD, Crohn’s disease, depression, Diabetes (Types 1 and 2), epilepsy, fibromyalgia, lupus, multiple sclerosis, NASH, obesity, osteoarthritis, psoriasis, and rheumatoid arthritis.

Michael Chekroun, Chief Strategy and Transformation Officer at EvidentIQ group and Founder of Carenity, tell us about this new offering:

“PatientLive has always offered quick responses and has been valued for its simplicity and autonomy of use. We want now to make this available for pharma companies focused on oncology and keep this virtuous circle of Data for Good going.”

More about PatientLive

PatientLive is a SaaS platform that allows users to acquire real-time insights through a five-question survey. Five types of questions are available: single choice, multiple choice, 0 to 5 scale, text field, numeric field, and image/video test. Users can access results in real-time, from day 1. Surveys on PatientLive initiate patients’ data generation on topics including: disease/treatment burden, unmet needs, quality of life, services and communication message testing, and information and service needs. These early insights are invaluable for PatientLive users as they enable better patient-centric solutions and materials, and may guide the development of further non-observational studies and Real World Evidence projects.

Number of vaccine refusers highest in France, lowest in the UK

Hamburg, 12.05.2021: Data science group EvidentIQ, with its subsidiary company Carenity, has published a survey with 3,353 participants on the situation of chronic patients during the pandemic. The target group included adults from France, the UK, Germany, Italy and the US. Among other findings regarding the number of canceled medical visits and procedures, or the rise of telehealth services, the difference in preparedness for vaccination per country stood out.

The motivation to get vaccinated does not come as a surprise. 48 percent state they are at risk, 46 percent want to protect others and 41 percent simply want to protect themselves from the virus. Only 18 percent indicate it would be easier to travel when vaccinated. The most frequent chronic conditions among the respondents are Type 2 diabetes (24%), asthma (19%), multiple sclerosis (15%) and COPD (14%). Given the severity of these illnesses, it is surprising that a mere 67 percent in France and 47 percent in Germany do not intend to get vaccinated.

Michael Chekroun, Chief Strategy and Transformation Officer of the EvidentIQ group and Founder of Carenity explains these results:

“When it comes to the COVID-19 vaccines, nearly half of our respondents are afraid of side effects. Another 45 percent name the lack of information as reason for their reluctance to be vaccinated. To some extent this is understandable.”

Chekroun refers to the comparably short development and trial phases of the new vaccines. For these highly regulated trial processes imposed by public entities like EMA and FDA – EvidentIQ provides software infrastructure, scientific services and even access to patients to secure and automate testing procedures.

“Many people are not aware that for extraordinary situations like these there have always been Accelerated Approval Programs to shorten time-to-market for a new treatment. This is obviously where chronic patients are understandably nervous, fearing side effects and requiring more information. Our survey shows that only 4 percent of all respondents generally oppose vaccination.”

Also, the survey shows that 46 percent report that medical visits or procedures have been canceled or postponed in the first wave of COVID-19, while 75 percent report the same for wave 2.

This may explain why roughly 67 percent of patients in the US are open to the use of telehealth consultations, in Europe only 47 percent.

Read the the full interview with Michael Chekroun on the outcome of this survey and get a free copy of the complete results.

Contact us for more information.